FDA Warns Shire About Vyvanse Marketing
The U.S. Food and Drug Administration earlier this month warned Shire PLC about misleading promotional materials for attention deficit hyperactivity disorder drug Vyvanse that did not include clearly visible risk information....To view the full article, register now.
Already a subscriber? Click here to view full article